Skip to content
DataLookout
Menu

NCT07476729

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Start date changed from estimate of Apr 1, 2026 to Sep 1, 2026
    • Eligibility criteria expanded, about 37 words
    • Study sites: 20 to 21
    • Secondary endpoints: details revised at 2 of 16 entries
    • Publications: details revised at 18 of 18 entries
    • Study description expanded, about 4 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

SR induction EFS
Timeframe: From enrollment until 2 years after end of treatment
SR-MRD good response consolidation DFS
Timeframe: From enrollment until 2 years after end of treatment
HR with CR2 consolidation DSF
Timeframe: From enrollment until 2 years after end of treatment
Isolated extramedullary manifestations: EFS
Timeframe: From enrollment until 2 years after end of treatment
SR induction: Pharmacokinetics Inotuzumab
Timeframe: from enrollment until day 28

Secondary (16)

SR induction: MRD
SR-MRD good response consolidation: OS
Isolated extramedullary manifestations: EFS
SR induction: allo-HSCT
SR induction: OS
Show 11 moreShow less
SR induction: Toxicity
SR induction: CD19 positive cells
SR-MRD good response consolidation: Toxicity
Isolated extramedullary manifestations: OS
Isolated extramedullary manifestations: DFS by MRD
HR with CR2 consolidation: OS
HR with CR2 consolidation: Toxicity
HR with CR2 consolidation: MRD
HR with CR2 consolidation: allo-HSCT
Inotuzumab PK
Inotuzumab PK exposure response relationship

Arms and interventions

SR inductionActive comparator

prospective, randomized 1:1, open label phase II/III trial comparing arm AI (ALLR3-MITOX) versus arm BI (InO). Randomization is stratified according to frontline treatment group (BFM, AIEOP, ALLTogether, other) and localization of relapse (BM+CNS, other)

SR MRD good response, consolidationActive comparator

single arm trial with 3 courses of blinatumomab, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the consolidation chemotherapy element SCB3, and the 3rd added on after the consolidation element SCB4 and 8 weeks of conventional maintenance therapy, then followed by conventional maintenance therapy being applied without reinduction chemotherapy pulses until week 132, as compared to historical controls (IntReALL BCP 2020 SR SOC induction arm compared with IntReALL SR 2010 arm B without epratuzumab)

HR with CR2, consolidationActive comparator

single arm trial with HC1 and 1 course of blinatumomab followed by allo-HSCT compared with historical controls

Isolated extramedullary manifestationsActive comparator

single arm trial with the IntReALL SR 2010 Arm A (ALL-REZ BFM 2002) including blinatumomab replacing the chemotherapy element SCA3 compared with historical controls. SR patients will receive further conventional consolidation, local irradiation and maintenance, HR patients will be given allo-HSCT after blinatumomab

Drugs: Inotuzumab ozogamicin (INO), Blinatumomab

Sites

21 sites in 21 countries

Austria 1, Belgium 1, Czechia 1, Denmark 1, Finland 1, France 1, Germany 1, Hungary 1, Israel 1, Italy 1, Netherlands 1, Norway 1, Poland 1, Portugal 1, Romania 1, Slovakia 1, Slovenia 1, Spain 1, Sweden 1, Switzerland 1, Turkey (Türkiye) 1